Matthew A. Powell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Matthew A. Powell has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Heather A. Lankes
NRG Oncology Statistics & Data Management Center, Roswell Park Cancer Institute, Buffalo, NY 14263, United States
4 shared publications - David Michael Mutch
Department of Human Health and Nutritional Sciences University of Guelph Guelph Ontario Canada
3 shared publications - Andrea R. Hagemann
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, St Louis, MO, United States
2 shared publications - David Piwnica-Worms
Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2 shared publications - Dirk Spitzer
Department of Surgery, Washington University School of Medicine, St. Louis, USA
2 shared publications Emily Berry
Northwestern Medicine Prentice Women's Hospital, Chicago, IL, USA https://dremilyberry.com
2 shared publications
Latest Publications
- 1 December 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 155 (3) , 393-399
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study
- 1 December 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 155 (3) , 393-399
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study
- Open Access
Synuclein‐γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study
BACKGROUND: Synuclein‐γ (SNCG) is highly expressed in advanced solid tumors, including uterine serous carcinoma (USC). The objective of the current study was to determine whether SNCG protein was associated with survival and clinical covariates using the largest existing collection of USCs from the Gynecologic Oncology Group (GOG‐8023).METHODS: High‐density tissue microarrays (TMAs) of tumor tissues from 313 patients with USC were stained by immunohistochemistry for SNCG, p53, p16, FOLR1, pERK, pAKT, ER, PR, and HER2/neu. Associations of SNCG and other tumor markers with overall and progression‐free survival were assessed using log‐rank tests and Cox proportional‐hazards models, which also were adjusted for age, race, and stage.RESULTS: The overall survival at 5 years was 46% for women with high SNCG expression and 62% for those with low SNCG expression (log‐rank P = .021; hazard ratio [HR], 1.31; 95% confidence interval [CI], 0.91‐1.9 in adjusted Cox model). The progression‐free survival rate at 5 years was worse for women who had high SNCG expression, at 40%, compared with 56% for those who had low SNCG expression (log‐rank P = .0081; HR, 1.36; 95% CI, 0.96‐1.92 in adjusted Cox model). High levels of both p53 and p16 were significantly associated with worse overall survival (p53: HR, 4.20 [95% CI, 1.54‐11.45]; p16: HR, 1.95 [95% CI, 1.01‐3.75]) and progression‐free survival (p53: HR, 2.16 [95% CI, 1.09‐4.27]; p16: HR, 1.53 [95% CI, 0.87‐2.69]) compared with low levels.CONCLUSIONS: This largest collection of USCs to date demonstrates that SNCG was associated with poor survival in univariate analyses. SNCG does not predict survival outcome independent of p53 and p16 in models that jointly consider multiple markers. Cancer 2017;123:1144–1155. © 2016 American Cancer Society.
Open AccessSynuclein‐γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study
BACKGROUND: Synuclein‐γ (SNCG) is highly expressed in advanced solid tumors, including uterine serous carcinoma (USC). The objective of the current study was to determine whether SNCG protein was associated with survival and clinical covariates using the largest existing collection of USCs from the Gynecologic Oncology Group (GOG‐8023).METHODS: High‐density tissue microarrays (TMAs) of tumor tissues from 313 patients with USC were stained by immunohistochemistry for SNCG, p53, p16, FOLR1, pERK, pAKT, ER, PR, and HER2/neu. Associations of SNCG and other tumor markers with overall and progression‐free survival were assessed using log‐rank tests and Cox proportional‐hazards models, which also were adjusted for age, race, and stage.RESULTS: The overall survival at 5 years was 46% for women with high SNCG expression and 62% for those with low SNCG expression (log‐rank P = .021; hazard ratio [HR], 1.31; 95% confidence interval [CI], 0.91‐1.9 in adjusted Cox model). The progression‐free survival rate at 5 years was worse for women who had high SNCG expression, at 40%, compared with 56% for those who had low SNCG expression (log‐rank P = .0081; HR, 1.36; 95% CI, 0.96‐1.92 in adjusted Cox model). High levels of both p53 and p16 were significantly associated with worse overall survival (p53: HR, 4.20 [95% CI, 1.54‐11.45]; p16: HR, 1.95 [95% CI, 1.01‐3.75]) and progression‐free survival (p53: HR, 2.16 [95% CI, 1.09‐4.27]; p16: HR, 1.53 [95% CI, 0.87‐2.69]) compared with low levels.CONCLUSIONS: This largest collection of USCs to date demonstrates that SNCG was associated with poor survival in univariate analyses. SNCG does not predict survival outcome independent of p53 and p16 in models that jointly consider multiple markers. Cancer 2017;123:1144–1155. © 2016 American Cancer Society.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 5517
A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian (EOC), fallopian tube, or peritoneal cancer who are in second or third complete remission.
5517 Background: Phase I data have demonstrated induction of antibody responses to a polyvalent vaccine conjugate (Globo-H, GM2, MUC1-TN, TF) with adjuvant OPT-821. We sought to determine if this combination decreases the hazard of progression versus OPT-821 alone in patients with EOC in second or third clinical complete remission (cCR) following chemotherapy. Secondary objectives were overall survival (OS), safety and immunogenicity. Methods: Patients were randomized (1:1) to receive OPT-821 + vaccine conjugate subcutaneously at weeks 1, 2, 3, 7, 11 and then every 12 weeks (total 11) Dose delay or reduction was not permitted. Patients were removed for pre-defined DLT. Randomized patients were evaluated for efficacy. Results: Between 2010 and 2013 171 patients were randomized; 170 treated. Most received 2 prior regimens (68%), had serous carcinoma (85%), stage 3 disease at diagnosis (77%), and no bevacizumab (67%). 54% received > 6 cycles treatment [median 6 in each arm (p = 0.33)]. 77% of patients discontinued due to progression, 4% due to toxicity, and 1 due to MDS. Maximum toxicity was grade 5 (n = 1, unrelated), grade 4 MDS and depression (n=2, unlikely), grade 3 GI disorders + others (n = 20, 4 related). Most common lesser adverse events were injection site reactions (84%) and fever (19%). (+) immunogenicity is defined as 1:40 or two fold increase. Estimated hazard ratio for PFS of vaccine conjugate + OPT-821 to OPT-821 arm was 0.98 (95% CI: 0.71-1.36). At followup of 34 months, median OS for OPT-821 is 47 months and not reached for vaccine conjugate + OPT-821. Conclusions: Vaccination with this polyvalent construct was modestly immunogenic and does not prolong PFS when compared to OPT-821 alone. The secondary OS endpoint requires additional followup. The second and third remission cohort is a feasible and well defined population to explore innovative consolidation or maintenance approaches. Clinical trial information: NCT00857545.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 5517
A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian (EOC), fallopian tube, or peritoneal cancer who are in second or third complete remission.
5517 Background: Phase I data have demonstrated induction of antibody responses to a polyvalent vaccine conjugate (Globo-H, GM2, MUC1-TN, TF) with adjuvant OPT-821. We sought to determine if this combination decreases the hazard of progression versus OPT-821 alone in patients with EOC in second or third clinical complete remission (cCR) following chemotherapy. Secondary objectives were overall survival (OS), safety and immunogenicity. Methods: Patients were randomized (1:1) to receive OPT-821 + vaccine conjugate subcutaneously at weeks 1, 2, 3, 7, 11 and then every 12 weeks (total 11) Dose delay or reduction was not permitted. Patients were removed for pre-defined DLT. Randomized patients were evaluated for efficacy. Results: Between 2010 and 2013 171 patients were randomized; 170 treated. Most received 2 prior regimens (68%), had serous carcinoma (85%), stage 3 disease at diagnosis (77%), and no bevacizumab (67%). 54% received > 6 cycles treatment [median 6 in each arm (p = 0.33)]. 77% of patients discontinued due to progression, 4% due to toxicity, and 1 due to MDS. Maximum toxicity was grade 5 (n = 1, unrelated), grade 4 MDS and depression (n=2, unlikely), grade 3 GI disorders + others (n = 20, 4 related). Most common lesser adverse events were injection site reactions (84%) and fever (19%). (+) immunogenicity is defined as 1:40 or two fold increase. Estimated hazard ratio for PFS of vaccine conjugate + OPT-821 to OPT-821 arm was 0.98 (95% CI: 0.71-1.36). At followup of 34 months, median OS for OPT-821 is 47 months and not reached for vaccine conjugate + OPT-821. Conclusions: Vaccination with this polyvalent construct was modestly immunogenic and does not prolong PFS when compared to OPT-821 alone. The secondary OS endpoint requires additional followup. The second and third remission cohort is a feasible and well defined population to explore innovative consolidation or maintenance approaches. Clinical trial information: NCT00857545.
- 1 November 2014
- Published by Elsevier in Gynecologic Oncology
- Vol. 135 (2) , 407
Survival of cervical cancer patients presenting with isolated supraclavicular metastases vs. extra-nodal disease, as assessed by positron-emission tomography (PET) scans
- 1 November 2014
- Published by Elsevier in Gynecologic Oncology
- Vol. 135 (2) , 407
Survival of cervical cancer patients presenting with isolated supraclavicular metastases vs. extra-nodal disease, as assessed by positron-emission tomography (PET) scans
- 1 October 2014
- Published by Elsevier in Gynecologic Oncology
- Vol. 135 (1) , 38-43
A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
- 1 October 2014
- Published by Elsevier in Gynecologic Oncology
- Vol. 135 (1) , 38-43
A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
- Open Access
- 7 March 2014
- Published by Springer Nature in Molecular Cancer
- Vol. 13 (1) , 50
Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer
Drug resistance is a significant problem in the treatment of ovarian cancer and can be caused by multiple mechanisms. Inhibition of apoptosis by the inhibitor of apoptosis proteins (IAPs) represents one such mechanism, and can be overcome by a mitochondrial protein called second mitochondria-derived activator of caspases (SMAC). We have previously shown that the ligands of sigma-2 receptors effectively induce tumor cell death. Additionally, because sigma-2 receptors are preferentially expressed in tumor cells, their ligands provide an effective mechanism for selective anti-cancer therapy. In the current work, we have improved upon the previously described sigma-2 ligand SW43 by conjugating it to a pro-apoptotic small molecule SMAC mimetic SW IV-52, thus generating the novel cancer therapeutic SW IV-134. The new cancer drug was tested for receptor selectivity and tumor cell killing activity in vitro and in vivo. We have shown that SW IV-134 retained adequate sigma-2 receptor binding affinity in the context of the conjugate and potently induced cell death in ovarian cancer cells. The cell death induced by SW IV-134 was significantly greater than that observed with either SW43 or SW IV-52 alone and in combination. Furthermore, the intraperitoneal administration of SW IV-134 significantly reduced tumor burden and improved overall survival in a mouse xenograft model of ovarian cancer without causing significant adverse effects to normal tissues. Mechanistically, SW IV-134 induced degradation of cIAP-1 and cIAP-2 leading to NF-қB activation and TNFα-dependent cell death. Our findings suggest that coupling sigma-2 ligands to SMAC peptidomimetics enhances their effectiveness while maintaining the cancer selectivity. This encouraging proof-of-principle preclinical study supports further development of tumor-targeted small peptide mimetics via ligands to the sigma-2 receptor for future clinical applications.
- 7 March 2014
- Published by Springer Nature in Molecular Cancer
- Vol. 13 (1) , 50
Open AccessConjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer
Drug resistance is a significant problem in the treatment of ovarian cancer and can be caused by multiple mechanisms. Inhibition of apoptosis by the inhibitor of apoptosis proteins (IAPs) represents one such mechanism, and can be overcome by a mitochondrial protein called second mitochondria-derived activator of caspases (SMAC). We have previously shown that the ligands of sigma-2 receptors effectively induce tumor cell death. Additionally, because sigma-2 receptors are preferentially expressed in tumor cells, their ligands provide an effective mechanism for selective anti-cancer therapy. In the current work, we have improved upon the previously described sigma-2 ligand SW43 by conjugating it to a pro-apoptotic small molecule SMAC mimetic SW IV-52, thus generating the novel cancer therapeutic SW IV-134. The new cancer drug was tested for receptor selectivity and tumor cell killing activity in vitro and in vivo. We have shown that SW IV-134 retained adequate sigma-2 receptor binding affinity in the context of the conjugate and potently induced cell death in ovarian cancer cells. The cell death induced by SW IV-134 was significantly greater than that observed with either SW43 or SW IV-52 alone and in combination. Furthermore, the intraperitoneal administration of SW IV-134 significantly reduced tumor burden and improved overall survival in a mouse xenograft model of ovarian cancer without causing significant adverse effects to normal tissues. Mechanistically, SW IV-134 induced degradation of cIAP-1 and cIAP-2 leading to NF-қB activation and TNFα-dependent cell death. Our findings suggest that coupling sigma-2 ligands to SMAC peptidomimetics enhances their effectiveness while maintaining the cancer selectivity. This encouraging proof-of-principle preclinical study supports further development of tumor-targeted small peptide mimetics via ligands to the sigma-2 receptor for future clinical applications.
- Open Access
- 21 January 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 35
Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3
The targeted delivery of cancer therapeutics represents an ongoing challenge in the field of drug development. TRAIL is a promising cancer drug but its activity profile could benefit from a cancer-selective delivery mechanism, which would reduce potential side effects and increase treatment efficiencies. We recently developed the novel TRAIL-based drug platform TR3, a genetically fused trimer with the capacity for further molecular modifications such as the addition of tumor-directed targeting moieties. MUC16 (CA125) is a well characterized biomarker in several human malignancies including ovarian, pancreatic and breast cancer. Mesothelin is known to interact with MUC16 with high affinity. In order to deliver TR3 selectively to MUC16-expressing cancers, we investigated the possibility of targeted TR3 delivery employing the high affinity mesothelin/MUC16 ligand/receptor interaction.
- 21 January 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 35
Open AccessNovel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3
The targeted delivery of cancer therapeutics represents an ongoing challenge in the field of drug development. TRAIL is a promising cancer drug but its activity profile could benefit from a cancer-selective delivery mechanism, which would reduce potential side effects and increase treatment efficiencies. We recently developed the novel TRAIL-based drug platform TR3, a genetically fused trimer with the capacity for further molecular modifications such as the addition of tumor-directed targeting moieties. MUC16 (CA125) is a well characterized biomarker in several human malignancies including ovarian, pancreatic and breast cancer. Mesothelin is known to interact with MUC16 with high affinity. In order to deliver TR3 selectively to MUC16-expressing cancers, we investigated the possibility of targeted TR3 delivery employing the high affinity mesothelin/MUC16 ligand/receptor interaction.
- 1 June 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (16) , 2727-2731
Phase II Evaluation of Paclitaxel and Carboplatin in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study
Purpose: Platinum and taxane compounds have demonstrated activity in uterine carcinosarcoma (malignant mixed Mullerian tumor). Ifosfamide plus paclitaxel is the regimen with established superiority based on a randomized phase III trial conducted through the Gynecologic Oncology Group. However, the toxicity, multiday schedule, and limited activity of this regimen support further development of novel regimens. Our primary objective was to estimate the antitumor activity and toxicity of paclitaxel plus carboplatin in patients with uterine carcinosarcomas. Patients and Methods: Eligible patients had advanced stage (III or IV), persistent or recurrent measurable disease, and no prior chemotherapy. Patients received paclitaxel at 175 mg/m2 intravenously (IV) over 3 hours plus carboplatin (area under the serum concentration-time curve = 6) IV over 30 minutes every 3 weeks until disease progression or until adverse effects occurred. Common Terminology Criteria for Adverse Events v3.0 was used to grade adverse events. Results: Fifty-five patients were entered onto the study with nine being excluded from analysis, leaving 46 evaluable for analysis. Treatment was well tolerated with expected hematologic toxicity and minimal nonhematologic grade 4 toxicity (one cardiovascular and two pain) with 59% of patients completing six or more cycles of chemotherapy. The proportions of patients with confirmed complete and partial responses were 13% and 41%, respectively, resulting in a total overall response rate of 54% (95% CI, 37% to 67%). Conclusion: Paclitaxel plus carboplatin demonstrates antitumor activity against uterine carcinosarcoma with acceptable toxicity and warrants further evaluation in phase III randomized trials.
- 1 June 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (16) , 2727-2731
Phase II Evaluation of Paclitaxel and Carboplatin in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study
Purpose: Platinum and taxane compounds have demonstrated activity in uterine carcinosarcoma (malignant mixed Mullerian tumor). Ifosfamide plus paclitaxel is the regimen with established superiority based on a randomized phase III trial conducted through the Gynecologic Oncology Group. However, the toxicity, multiday schedule, and limited activity of this regimen support further development of novel regimens. Our primary objective was to estimate the antitumor activity and toxicity of paclitaxel plus carboplatin in patients with uterine carcinosarcomas. Patients and Methods: Eligible patients had advanced stage (III or IV), persistent or recurrent measurable disease, and no prior chemotherapy. Patients received paclitaxel at 175 mg/m2 intravenously (IV) over 3 hours plus carboplatin (area under the serum concentration-time curve = 6) IV over 30 minutes every 3 weeks until disease progression or until adverse effects occurred. Common Terminology Criteria for Adverse Events v3.0 was used to grade adverse events. Results: Fifty-five patients were entered onto the study with nine being excluded from analysis, leaving 46 evaluable for analysis. Treatment was well tolerated with expected hematologic toxicity and minimal nonhematologic grade 4 toxicity (one cardiovascular and two pain) with 59% of patients completing six or more cycles of chemotherapy. The proportions of patients with confirmed complete and partial responses were 13% and 41%, respectively, resulting in a total overall response rate of 54% (95% CI, 37% to 67%). Conclusion: Paclitaxel plus carboplatin demonstrates antitumor activity against uterine carcinosarcoma with acceptable toxicity and warrants further evaluation in phase III randomized trials.
- 14 October 2009
- Published by Springer Nature in Current Oncology Reports
- Vol. 11 (6) , 466-472
Novel imaging modalities in gynecologic cancer
Novel imaging modalities continue to emerge in medicine, and the advent of 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) has had a significant impact in the imaging of gynecologic malignancies. In cervical cancer, FDG-PET has excellent sensitivity and specificity for evaluation of initial disease, as well as assessment of post-treatment response and long-term surveillance. In ovarian cancer, FDG-PET can be a useful tool in assessing recurrent disease, especially in the setting of a rising cancer antigen-125 with a negative or equivocal CT or MRI. In uterine cancer, FDG-PET has been investigated in evaluating the extent of disease including nodal metastases, and in assessing recurrence. This article reviews novel imaging modalities in gynecologic cancer, with a special focus on FDG-PET/CT.
- 14 October 2009
- Published by Springer Nature in Current Oncology Reports
- Vol. 11 (6) , 466-472
Novel imaging modalities in gynecologic cancer
Novel imaging modalities continue to emerge in medicine, and the advent of 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) has had a significant impact in the imaging of gynecologic malignancies. In cervical cancer, FDG-PET has excellent sensitivity and specificity for evaluation of initial disease, as well as assessment of post-treatment response and long-term surveillance. In ovarian cancer, FDG-PET can be a useful tool in assessing recurrent disease, especially in the setting of a rising cancer antigen-125 with a negative or equivocal CT or MRI. In uterine cancer, FDG-PET has been investigated in evaluating the extent of disease including nodal metastases, and in assessing recurrence. This article reviews novel imaging modalities in gynecologic cancer, with a special focus on FDG-PET/CT.